1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Stada Raises Sales And Earnings But Admits ‘Tough’ Q2

Organic And Inorganic Moves Drive Growth

 
• By Dean Rudge

Privately-owned Stada provided little insight into the exact mechanics of its operations for the first six months of 2020 but nevertheless said it had enjoyed an “above-market sales and earnings increase.” However, a raft of one-off expenses bit into the German firm’s profitability.

business documents accounting with calculator and magnifying glass. concept for financial
Stada's group sales as reported increased by 16% to €1.47bn • Source: Shutterstock

Stada welcomed an “above-market sales and earnings increase” in the first half of this year, with the firm’s Generics sales increasing by 12% to €833.4m ($986m), driven by sales increases in major European markets alongside the acquisition of a product portfolio from Switzerland’s Opti Pharm.

Increased sales in its native Germany, where Stada’s Aliud Pharma subsidiary “did well,” alongside Italy, Belgium and France, helped Stada’s Generics operation in the six months to 30 June. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

Krka Looks To Kick On In India And China

 
• By Dean Rudge

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

Zydus To Continue Mirabegron Sales

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list.

Sawai Reports ‘Solid Overall’ Full Year Results Despite Some Misses

 
• By Adam Zamecnik

Continuing in its medium-term business plan and company reform, Sawai forecasts its revenue to exceed ¥200bn in the coming fiscal year.

More from Business

Krka Looks To Kick On In India And China

 
• By Dean Rudge

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

Teva Brings In European Trastuzumab With Prestige BioPharma Agreement

 
• By Dean Rudge

Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.